Adverse effects/events: death ‐ all‐cause mortality(assessed by patient records) · recent‐onset psychosis
Extended specialised early intervention (SEI) teams showed no clear difference in adverse effects/events: death ‐ all‐cause mortality(assessed by… compared with standard SEI teams plus treatment (low certainty).
1 finding from 1 review
All‐cause mortality Up to 6 weeks post‐natally · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 46 days post‐operatively compared with inactive Control (high certainty).
1 finding from 1 review
All‐cause mortality Up to 28 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
2 findings from 1 review
All‐cause mortality Up to 28 days following admission · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality Up to 28 days following admission compared with inactive Control (moderate certainty).
1 finding from 1 review
All‐cause mortality Up to 7 days post‐operatively or hospital discharge · the prevention and treatment of bleeding in patients without haemophilia
1 finding from 1 review
All‐cause mortality In‐hospital mortality up to 30 days post‐operatively · the prevention and treatment of bleeding in patients without haemophilia
FIBRINOGEN: Therapeutic trials: intervention showed no clear difference in all‐cause mortality In‐hospital mortality up to 30 days… compared with inactive Control (low certainty).
1 finding from 1 review
All‐cause mortality at end of intervention (range 2–10 months) · adult patients after liver transplantation.
It is very uncertain whether exercise changes all‐cause mortality at end of intervention (range 2–10 months) compared with control (very low certainty).
1 finding from 1 review
All‐cause mortality (between start of intervention and end of · preterm infants
Enteral zinc supplementation may leads to lower all‐cause mortality (between start of intervention and end of compared with no zinc supplementation (low certainty).
1 finding from 1 review
Long‐term all‐cause mortality (≥ 1 year after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes long‐term all‐cause mortality (≥ 1 year after the intervention) compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Short‐term all‐cause mortality (within the first 30 days after the intervention) · people with STEMI and MVD.
It is very uncertain whether complete revascularisation changes short‐term all‐cause mortality (within the first 30 days after the… compared with culprit‐only revascularisation (very low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs placebo [30 weeks to 4.75 years] b. Intervention vs insulin [4.75 years to 10.0 years] · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs placebo [30 weeks to 4.75… (low certainty).
1 finding from 1 review
Intervention not reported
All‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4 years] b. Intervention vs thiazolidinediones [b. 24 weeks to 4 years] c. Intervention vs insulin [c. 9 months to 10 years] d. Intervention vs incretin‐based control [d. 52 weeks to... · participants with type 2 diabetes mellitus
The intervention showed no clear difference in all‐cause mortality a. Intervention vs metformin [a. 24 weeks to 4… (low certainty).
1 finding from 1 review
All‐cause mortality · children with portal hypertension and large oesophageal varices, without previous gastrointestinal bleeding or beta‐blocker treatment
It is very uncertain whether band ligation changes all‐cause mortality compared with sham or no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether portosystemic shunts changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether distal splenorenal shunt changes all‐cause mortality compared with endoscopic intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether transjugular intrahepatic portosystemic shunt changes all‐cause mortality compared with endoscopic intervention with or without medical treatment (very low certainty).
1 finding from 1 review
All‐cause mortality · participants with cirrhosis and with previous oesophagogastric variceal bleeding
It is very uncertain whether total shunt changes all‐cause mortality compared with endoscopic intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · primary prophylaxis of oesophageal variceal bleeding in children with chronic liver disease or portal vein thrombosis
It is very uncertain whether sclerotherapy changes all‐cause mortality compared with no intervention (very low certainty).
1 finding from 1 review
All‐cause mortality · chronic hepatitis B
1 finding from 1 review